TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives $12.67 Consensus Price Target from Brokerages

TuHURA Biosciences, Inc. (NASDAQ:HURA) has received an average rating of “Buy” from the six analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $12.6667.

HURA has been the subject of several research analyst reports. Wall Street Zen upgraded shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Brookline Capital Management upgraded shares of TuHURA Biosciences to a “strong-buy” rating in a research report on Monday, June 23rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Saturday, September 27th.

Institutional Investors Weigh In On TuHURA Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC purchased a new stake in TuHURA Biosciences in the 4th quarter worth approximately $138,000. Squarepoint Ops LLC purchased a new stake in TuHURA Biosciences in the 4th quarter worth approximately $223,000. Sabal Trust CO purchased a new stake in TuHURA Biosciences in the 1st quarter worth approximately $127,000. Invst LLC purchased a new stake in TuHURA Biosciences in the 1st quarter worth approximately $61,000. Finally, Apollon Wealth Management LLC lifted its position in TuHURA Biosciences by 86.0% in the 1st quarter. Apollon Wealth Management LLC now owns 114,926 shares of the company’s stock worth $371,000 after buying an additional 53,154 shares in the last quarter. Hedge funds and other institutional investors own 0.62% of the company’s stock.

TuHURA Biosciences Stock Performance

Shares of NASDAQ:HURA opened at $2.49 on Thursday. TuHURA Biosciences has a 52 week low of $1.80 and a 52 week high of $8.40. The firm has a 50 day simple moving average of $2.66 and a 200 day simple moving average of $3.02.

TuHURA Biosciences (NASDAQ:HURA) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.07).

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.